Slow cycling cell RNA based T cell therapy to prevent recurrence in GBM
基于慢循环细胞 RNA 的 T 细胞疗法可预防 GBM 复发
基本信息
- 批准号:10331046
- 负责人:
- 金额:$ 22.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:Adjuvant TherapyAdoptive Cell TransfersAnimalsAntigensAutologousAutomobile DrivingBiologyBrain NeoplasmsCell CycleCellsChemoresistanceClinicalClinical TreatmentClinical TrialsCollecting CellDendritic CellsDevelopmentDiseaseDisease modelEnvironmentEvolutionExcisionGlioblastomaGliomaGoalsHumanImmuneImmune TargetingImmune responseImmune systemImmunologicsImmunologyImmunotherapyIn VitroInterferonsIntravenousInvestigationInvestigational TherapiesLaboratoriesMalignant GliomaMalignant NeoplasmsMalignant neoplasm of brainModalityModelingMononuclearMusMutateNatureNeuraxisOperative Surgical ProceduresPathogenicityPatientsPeptidesPeripheralPeripheral Blood Mononuclear CellPhenotypePhysiologic pulsePlayPopulationPre-Clinical ModelPrognosisProtocols documentationRNARadiationRadiation therapyRadioRecurrenceRecurrent diseaseRecurrent tumorRefractoryRegimenRelapseReportingResearchResidual stateResistanceRoleRunningSeveritiesSourceSpecificitySurveysSystemT cell therapyT-Cell ActivationT-LymphocyteTestingTherapeuticTreatment EfficacyTumorigenicityVaccinesanticancer treatmentantigen-specific T cellsbasecancer therapyclinically relevantconventional therapycytotoxicdesignefficacy testingexperimental studyglioma cell lineimmunogenicimmunogenicityimprovedin vivoinnovationmouse modelneoantigensneoplastic cellnovelnovel strategiespreventrecruitrefractory cancerself-renewalslow potentialtemozolomidetherapy resistanttumortumor progression
项目摘要
PROJECT SUMMARY AND ABSTRACT
Conventional cancer treatments target fast-cycling cells, however slowly dividing populations tend to be spared
recapitulating the tumor via their self-renewing abilities. We reported the existence of slow-cycling cells (SCCs)
that are extremely resistant to therapies and play a critical role in recurrence of glioblastoma (GBM). Clinical
strategies able to target this specific phenotype hold great promises for improving prognosis.
Importantly, these pathogenic drivers demonstrated expression of predicted immunogenic antigens providing
therapeutic opportunities that we propose to exploit in the context of immunotherapy. We have established a
new platform for adoptive cellular therapy (ACT) employing the use of total tumor RNA-pulsed dendritic cells
(DCs) to expand tumor reactive T lymphocytes. We are currently testing in multiple clinical trials this treatment
modality in patients with brain tumors (ACTION-IND#17298, REMATCH-IND#14058, BRAVO-IND#17298).
The goal of this project is to leverage the power of this therapeutic platform to achieve robust targeting of
treatment-resistant clones using a novel model of recurrent GBM. We hypothesize that the cytotoxic activity of
tumor-specific T cells can be directed toward clones promoting recurrence by SCC RNA-pulsed dendritic cells,
thus impeding disease relapse.
To test our hypothesis, the specific aims of this proposal are to:
Aim 1. Determine the immunogenicity and efficacy of slow-cycling cell RNA-based T cell treatment in a preclinical
model of recurrent GBM
Aim 2. Evaluate the slow-cycling cell RNA-based T cell platform in a human autologous setting.
Successfully completed, this proposal has a strong likelihood to impact favorably on treatment options for
patients with malignant gliomas.
项目总结与摘要
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Comment on Mahajan, S.; Schmidt, M.H.H. Distinct Lineage of Slow-Cycling Cells Amidst the Prevailing Heterogeneity in Glioblastoma. Cancers 2023, 15, 3843.
- DOI:10.3390/cancers16020277
- 发表时间:2024-01-09
- 期刊:
- 影响因子:5.2
- 作者:Yang, Changlin;Mitchell, Duane A.;Deleyrolle, Loic P.
- 通讯作者:Deleyrolle, Loic P.
KR158 spheres harboring slow-cycling cells recapitulate GBM features in an immunocompetent system.
含有慢循环细胞的 KR158 球体再现了免疫活性系统中的 GBM 特征。
- DOI:10.1101/2024.01.26.577279
- 发表时间:2024
- 期刊:
- 影响因子:0
- 作者:Chakraborty,Avirup;Yang,Changlin;Kresak,JesseL;Silver,Aryeh;Feier,Diana;Tian,Guimei;Andrews,Michael;Sobanjo,OlusegunO;Hodge,EthanD;Engelbart,MiaK;Huang,Jianping;Harrison,JeffreyK;Sarkisian,MatthewR;Mitchell,DuaneA;Deleyr
- 通讯作者:Deleyr
Heterogeneity of glioblastoma stem cells in the context of the immune microenvironment and geospatial organization.
- DOI:10.3389/fonc.2022.1022716
- 发表时间:2022
- 期刊:
- 影响因子:4.7
- 作者:Silver, Aryeh;Feier, Diana;Ghosh, Tanya;Rahman, Maryam;Huang, Jianping;Sarkisian, Matthew R.;Deleyrolle, Loic P.
- 通讯作者:Deleyrolle, Loic P.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Loic Pierre Deleyrolle其他文献
Loic Pierre Deleyrolle的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Loic Pierre Deleyrolle', 18)}}的其他基金
Optimizing CAR T therapy via metabolic engineering for thetreatment of GBM
通过代谢工程优化 CAR T 疗法治疗 GBM
- 批准号:
10722922 - 财政年份:2023
- 资助金额:
$ 22.88万 - 项目类别:
Metabolic interactions between tumor cells and the immunce system in GBM A potential Achilles heel of GBM for novel therapeutics
GBM 中肿瘤细胞与免疫系统之间的代谢相互作用是 GBM 新疗法的潜在致命弱点
- 批准号:
10522529 - 财政年份:2022
- 资助金额:
$ 22.88万 - 项目类别:
Metabolic interactions between tumor cells and the immunce system in GBM A potential Achilles heel of GBM for novel therapeutics
GBM 中肿瘤细胞与免疫系统之间的代谢相互作用是 GBM 新疗法的潜在致命弱点
- 批准号:
10673172 - 财政年份:2022
- 资助金额:
$ 22.88万 - 项目类别: